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Lysophosphatidic acid (LPA) is an extracellular signaling lipid that regulates cell proliferation, survival, and motility of normal and cancer
cells. These effects are produced through G protein–coupled LPA receptors, LPA1 to LPA5. We generated an LPA1 mutant lacking the SerValVal
sequence of the C-terminal PDZ-binding domain to examine the role of this domain in intracellular signaling and other cellular functions. B103
neuroblastoma cells expressing the mutant LPA1 showed rapid cell proliferation and tended to form colonies under serum-free conditions. The
enhanced cell proliferation of the mutant cells was inhibited by exogenous expression of the plasmids inhibiting G proteins including Gβγ, Gαi and
Gαq or Gα12/13, or treatment with pertussis toxin, phosphoinositide 3-kinase (PI3K) inhibitors or a Rho inhibitor. We confirmed that the PI3K-Akt
and Rho pathways were intrinsically activated in mutant cells by detecting increases in phosphorylated Akt in western blot analyses or by directly
measuring Rho activity. Interestingly, expression of the mutant LPA1 in non-tumor mouse fibroblasts induced colony formation in a clonogenic
soft agar assay, indicating that oncogenic pathways were activated. Taken together, these observations suggest that the mutant LPA1 constitutively
activates the G protein signaling leading to PI3K-Akt and Rho pathways, resulting in enhanced cell proliferation.
© 2007 Elsevier B.V. All rights reserved.Keywords: Lysophosphatidic acid receptor; PDZ-binding domain; Phosphoinositide 3-kinase; Akt; Rho; Oncogenic signal1. Introduction
Lysophosphatidic acid (LPA), a growth factor–like phospho-
lipid, has been shown to exert diverse cellular functions that
influence cell growth, motility, morphology, and fate [1–7]. The
effects of LPA are mediated through specific G protein–coupled
LPA receptors, LPA1 and LPA2. lpa1, lpa2, and lpa3 genes are
structurally related each other, whereas lpa4 (GPR23) genes and
lpa5 (GPR92) are phylogenetically far from lpa1, lpa2 and lpa3,
and closer to the platelet-activating factor receptor [3,8–11]. LPA
receptor–mediated signaling is implicated not only in physiolo-
gical events but also in pathophysiological processes, such as⁎ Corresponding author. Research Institute for Science and Technology, Kinki
University, Kowakae 3-4-1, Higashiosaka 577-8502, Japan. Tel.: +81 6 6730
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doi:10.1016/j.bbamcr.2007.11.013cancer growth and vascular diseases. For example, LPA is known
to be present in the ascites of ovarian cancer patients and to
stimulate the proliferation of several types of cancer cells [12–14].
LPA1 was the first LPA receptor to be identified and couples
to three distinct families of G proteins, Gi, Gq, and G12 [1,15,16].
LPA receptor–mediated Gi stimulation activates theMAP kinase
and phosphoinositide 3-kinase (PI3K)–Akt pathways, resulting
in cell proliferation and cell survival, respectively. Gq proteins
activate phospholipase C, producing diacylglycerol and inositol
1,4,5-trispohosphate. The G12 family interacts with Rho guanine
nucleotide exchange factor (RhoGEF), which in turn stimulates
Rho, leading to cytoskeletal changes and activation of genes
related to cell proliferation.
G protein–coupled receptors (GPCRs) not only couple to
various G proteins but also to another type of protein, GPCR-
interacting proteins (GIPs), through specific domains or struc-
tures. Some GPCRs contain a PDZ-binding domain consisting
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This domain binds to PDZ-containing molecules and contributes
to the recruitment of functional protein complexes to positions
under the plasma membranes [17]. For instance, the 5-
hydroxytryptamine receptor (5-HT2A) interacts with PDZ-
containing proteins such as PSD-95 [18]. LPA2 harbors a PDZ-
binding domain that interacts with Na+/H+ exchanger regulatory
factor 2 (NHERF2), and this interaction defines the efficiency of
LPA2-mediated phospholipase C activation [19]. Although LPA1
also contains a SerValVal domain that interacts with PDZ-
RhoGEF [20], its cellular functions remain to be determined.
To investigate the distinct signaling pathways activated by
each LPA receptor, we generated clonal cells expressing each
wild-type LPA receptor as well as mutants of each receptor
lacking the C-terminus. While maintaining the clonal cells in
culture, we noticed that cells expressing the mutated lpa1 grew
faster than cells expressing wild-type receptors. In the present
study, we examined the role of the PDZ-binding domain of
LPA1 in cell proliferation. We demonstrate that the lack of the
PDZ-binding domain produces a constitutively active form of
LPA1, which enhances cell proliferation by activating PI3K-Akt
and the small GTPase Rho, and LPA1 antagonists function as
inverse agonists for the mutant LPA receptors.
2. Materials and methods
2.1. Cell culture
Rat B103 neuroblastoma cells and mouse Swiss/3T3 fibroblast cells were
maintained in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis,
MO) containing 10% fetal calf serum (FCS) and penicillin/streptomycin (Sigma).
2.2. Establishment of clones
Mouse lpa1 lacking the last three amino acids (SerValVal; lpa1Δ) and lpa1
with the last three amino acids replaced with AsnGlySer (lpa1Δ+) were prepared
by PCR using FLAG-tagged lpa1 as a template and subcloned into S001-AB
plasmids [15]. To generate LPA receptor–expressing clonal cells, we used
retroviruses co-expressing green fluorescent protein (GFP) from an internal
ribosomal entry site. Retroviruses expressing FLAG-tagged lpa1, lpa2, lpa3,
lpa1Δ, and lpa1Δ+were prepared by transfection of Phoenix cells with S001-AB
plasmids containing each LPA receptor, as previously described [15]. B103 cells
or 3T3 cells were infectedwith retroviruses expressing each LPA receptor gene in
the presence of 5 μg/ml polybrene (Sigma). Infected cells were harvested, and
about 100 cells were sparsely replated in a 15-cm-diameter plate. Colonies in
which all cells expressed GFP were picked up and propagated further.
2.3. RT-PCR
Total RNAs were prepared using Tri Reagent (Sigma), treated with RNase-
free DNase, and reverse-transcribed with oligo(dT)12-18 and Superscript
reverse transcriptase (all purchased from Invitrogen, Carlsbad, CA). The
resultant cDNAs (0.025 μg) were amplified by PCR using GoTaq (Promega,
Tokyo, Japan) for LPA receptor family members. The primers used were: for
lpa1, forward lpA1e3mh1 (5′-TCTTCTGGGCCATTTTCAAC-3′) and reverse
lpA1e4mh1 (5′-TGCCTGAAGGTGGCGCTCAT-3′), producing a 349-bp
product; for lpa2, lpA2e2mh1 (5′-CCTACCTCTTCCTCATGTTC-3′) and
lpA2e3mh1 (5′-TAAAGGGTGGAGTCCATCAG-3′), producing a 798-bp
product; and for lpa3, lpA3e1dmh (5′-GGAATTGCCTCTGCAACATCT-3′)
and lpA3e2mh1 (5′-GAGTAGATGATGGGGTTCA-3′), producing a 382-bp
product [16,21,22]; for PDZ-RhoGEF, rhpdzRG-s1 (5′-GAGCAGATCCAC-
GACTAC-3′) and rhpdzRG-as1 (5′-GATGTTCCTCACATTGCC-3′),producing a 465-bp product; for LARG, rhLARG-s1 (5′-GAGTGGCACA-
CAGTCTAC-3′) and rhLARG-as1 (5′-ACGAAGACTGGATTGTCTCC-3′),
producing a 279-bp product; for p115RhoGEF, rhp115RG-s1 (5′-
TCGAGGTGCATTCCCTGTTCC-3′) and rhp115RG-as1 (5′-CCTCAG-
CAGGTCCTCCATGT-3′), producing a 440-bp product; for Gα12, mrhG12-
s1 (5′-TCAAGCAGATGCGCATCA-3′) and mrhG12-as1 (5′-TCGAAG-
CACTGGAACCAC-3′), producing a 508-bp product; for Gα13, mrhG13-s1
(5′-CCCACCATCTACAGCAAC-3′) and mrhG13-as1 (5′-CCTTT-
GGTGGGTCTTCTG-3′), producing a 359-bp product. The cycling protocol
was 60 s at 94 °C; 27 cycles of 30 s at 94 °C, 30 s at 55 °C, and 90 s at 72 °C; and
7 min at 72 °C at the end of cycling to complete extension.
2.4. Western blot analysis
Cells were lysed with extraction buffer (50 mMTris-Cl, 150 mMNaCl, 1 mM
EDTA, 1% Triton X-100, 1x protease inhibitor cocktail [EMD Biosciences, San
Diego, CA], 1x phosphatase inhibitor cocktail [Sigma]), and the lysates were
centrifuged at 20,000×g for 5 min. The supernatants were mixed with 4x SDS-
sample buffer [23], boiled and separated in polyacrylamide gels. The proteins were
transferred to PVDF membranes (Millipore, San Jose, CA), and the membranes
were probed with a primary antibody. The antibodies were used at the following
dilutions: anti–FLAG polyclonal antibody (1:10,000, Sigma); anti–GFP poly-
clonal antibody (1:10,000, Clontech, Mountain View, CA); anti–cyclin B1
polyclonal antibody (100 ng/ml, Santa Cruz Biotechnology, Santa Cruz, CA); and
anti–phospho-Akt (Thr308) (1:2000), anti–Akt antibody (1:2000), and anti–
phospho-GSK3β polyclonal antibody (1:2000), all from Cell Signaling Technol-
ogy, Danvers, MA. Membranes were further incubated with a peroxidase-labeled,
anti-mouse IgG antibody (100 ng/ml, Jackson ImmunoResearch Laboratories,
West Groves, PA) or anti-rabbit IgG antibody (40 ng/ml, Santa Cruz
Biotechnology) and ECL plus (Amersham, Tokyo, Japan) and exposed to X-ray
film (RX-U, Fuji Film, Tokyo, Japan) for 15 to 180 sec, after which the film was
developed. The developed filmwas digitized using a flat-bet scanner (GT-9400UF,
Epson) and densitometric and quantitative analysis of signals was performed using
Scion Image 1.62 (Scion Corporation).
2.5. [35S]-GTPγS binding assay
[35S]-GTPγS binding assay was performed, as described previously [15,24].
Briefly, cell membranes (25 μg protein) were incubated with 0.1 nM [35S]-GTPγS
(1,200 Ci/mmol, GE healthcare, Tokyo, Japan) and 10 μM GDP for 30 min at 30
°C. The bound [35S]-GTPγS was separated from free by rapid filtration through
GF/C filters, and the filters were counted by liquid scintillation.
2.6. Rho assay
Rho activity was determined using G-LISA (Cytoskeleton, Denver, CO),
according to the manufacturer's protocol. Briefly, cells were extracted with ice-
cold lysis buffer, and the lysates were centrifuged at 20,000×g for 3 min. The
supernatant (50~120 μg protein) was applied to a 96-well G-LISA plate to
measure the active form of Rho. A colorimetric reaction showed a linear
response to time after the addition of chromogenic substrate, and data were
collected as absorbance per microgram of protein.
2.7. Cell proliferation assay
Cells were plated at 5000 cells/well in a 48-well plate and cultured for 1 day.
Cells were washed with serum-free DMEM and further cultured with 200 μl
serum-free DMEM for B103 clones or 0.5% FCS-containing DMEM for 3T3
clones. Solution from a Cell Counting Kit (10 μl, Dojin Chemistry, Kumamoto,
Japan) was added to the plate, which was further incubated for 1 hour. The
absorbance of the culture medium at 450 nm was determined. This assay was
always done in triplicate or quadruplicate.
2.8. [3H]-Thymidine uptake assay
Cells were plated at 10,000 to 20,000 cells/well in a 24-well plate. The day
after plating, the cells were washed with serum-free DMEM and further
Fig. 1. Established clones express the LPA receptors corresponding to the
infected constructs and GFP. (A) RT-PCR analysis for LPA receptor gene
expression in each clone. (B) Western blot analysis for LPA receptor protein and
GFP. In this analysis, we intentionally induced the formation of receptor protein
aggregates by boiling cellular extracts, which appeared between 120∼220 kDa of
molecular mass, because B103 cells frequently showed non-specific signals
around 45 kDa,which overlapped non-aggregated LPA receptor signals ([15] and
data not shown). (C) Phase contrast (upper panel) and fluorescent (lower panel)
micrographs of each clone showing GFP expression in all cells. Scale bar, 10 μm.
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thymidine (0.5 μCi/ml, American Radiolabeled Chemicals, St. Louis, MO) for
4 h, washed with ice-cold PBS, and lysed with 200 μl of 0.2 M NaOH. The
lysates were transferred to a 1.5-ml tube and mixed with 40 μl of 1 M HCl and
60 μl of 100% trichloric acid (TCA). DNAs were precipitated by
centrifugation at 15,000×g and washed with 5% TCA. The DNAs were
solubilized with 0.1 M NaOH and radioactivity was measured by a
scintillation counter.
2.9. Soft agar assay
Cells were suspended in DMEM containing 0.4% low-melting-point
agarose (Amresco, Solon, OH) and 10% FCS and plated on a bottom layer
containing 0.8% agarose.
2.10. Construction of GRK2ct, RGS4 and p115RGS plasmids
The genes encoding the C terminal region (453-647 amino acid) of G
protein-coupled receptor kinase2 (GRK2ct) and regulator of G protein
signaling 4 (RGS4) were amplified by PCR using mouse brain cDNAs and
a set of specific primers. The PCR product was subcloned into the pcDNAIII-
myc plasmid, which we generated as an expression plasmid for an N-terminal
myc-tagged protein. The gene encoding the RGS domain (16-267 amino acid) of
p115RhoGEF (p115RGS) was amplified by PCR using myc-tagged p115Rho-
GEF (provided by Dr. Kozasa, University of Illinois). The extra four amino acids
(CysValLeuLeu) were added at the end of the RGS domain. The PCR product
was subcloned into the pcDNAIII. These plasmids were sequenced and the
sequence identities were confirmed. Protein expression of these mutants in
mammalian cells was also confirmed bywestern blotting using an anti-Myc 9E10
antibody (Santa Cruz Biotechnology).
2.11. Transfection
Cells were transfected with expression plasmids using Lipofectamine LTX
(Invitrogen). Cells were seeded on poly-lysine–coated glass coverslips (5000
cells/12-mm diameter) and incubated for 15 h with DNA-lipid complex
(0.1 μg DNA-0.3 μl Lipofectamine LTX/cm2). Cells were washed and further
cultured in serum-free DMEM for 1 day prior to use.
2.12. Immunocytochemistry
Cells were fixed for 15 min with 3.7% formaldehyde and washed with
phosphate-buffered saline (PBS), then blocked and permeabilized with 10%
normal goat serum and 0.2% Triton X-100. In some experiments to detect
extracellular FLAG tag, Triton X-100 was omitted. Cells were then incubated
with an anti-FLAGM2 antibody (1 μg/ml, Sigma), followed by incubation with
Alexa546-labeled anti-mouse IgG antibodies (5 μg/ml, Invitrogen). For double
staining, cells were incubated with an anti-Myc 9E10 antibody (1 μg/ml) as a
primary antibody, followed by incubation with Alexa350-labeled anti-mouse
IgG antibodies (5 μg/ml, Invitrogen). Cells were further immunostained with an
anti–phospho-histone H3 polyclonal antibody (5 μg/ml, Upstate, Charlottes-
ville, VA), followed by incubation with an Alexa546-labeled anti-rabbit IgG
antibody (2 μg/ml, Invitrogen). About 200 total cells or transfected cells per
coverslip were observed with a fluorescent microscope (Axioskop, Carl Zeiss,
Tokyo, Japan) and a 40x objective (Plan Neofluar), and counted in at least 5
randomly selected fields.
2.13. Pharmacological reagents
Pertussis toxin was purchased from Wako (Osaka, Japan). Wortmannin,
deguelin, and triciribin were from EMD Biosciences. LY294002 was from Cell
Signaling Technology. Ki16425 and Ki16198 were provided by the Kirin
Brewery Company (Gunma, Japan). YM-254890 was from the Astellas
Pharmaceutical Company (Tokyo, Japan). The recombinant hexahistidine-
tagged C3 exoenzyme was generated as previously described [24].2.14. Statistical methods
Analysis of variance (ANOVA) followed by a post hoc test was applied to
data to determine statistical significance by using the statistical software,
StatView 4.5 (Abacus Concepts).3. Results
3.1. Cells expressing an LPA1 mutant grow continuously
To examine the functions of lpa1, lpa2 and lpa3, we generated
clonal cells expressing each LPA receptor subtype using B103 rat
neuroblastoma cells, because parent B103 cells express no
detectable levels of any endogenous LPA receptor genes and
show no response to LPA [9,15,24]. The clonal cells, designated
AB2-1bf (control clone), lpa1-1 (lpa1-expressing clone), lpa2-2
(lpa2-expressing clone), and lpa3-3-2 (lpa3-expressing clone),
were established by retroviral infection and subsequent single-cell
cloning. As expected, the established cells expressed the cor-
respondingLPA receptor genes and proteins andGFP (Fig. 1A-C).
The shapes of the clonal cells were largely indistinguishable from
those of the parental B103 and control AB2-1bf cells, except for
clone lpa3-3-2 expressing the lpa3 gene, which showed rounded
cell bodies, multiple neuritic processes, and branches extending
from their processes (Fig. 1C).
We also generated two lpa1 mutant clonal cells to exam-
ine how a putative PDZ-binding domain (SerValVal) of the
C-terminal region might function in cell signaling. The mutant
clone lpa1Δ-1 expressed lpa1Δ, which lacks the C-terminal
SerValVal, and the mutant clone lpa1Δ+-1 expressed lpa1Δ+,
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C-terminal amino acids of LPA3. These cells also the corre-
sponding genes and proteins as well as GFP (Fig. 1A-C). We
examined whether LPA1 mutants could respond to LPA with
activation of intracellular signaling. When lpa1Δ-1 cell mem-
branes or cells were treated with LPA, increases in [35S]-GTPγS
binding in cell membranes and Rho activities were observedFig. 2. LPA1Δmaintains the functionality as an LPA receptor. (A) Effects of LPA on [
3
in serum-free medium for 1 day and subjected to [35S]-GTPγS binding assay. Basal [3
mg protein (also shown as Fig. 4 C). Data are expressed as a percentage of control (no L
LPA on Rho activities in AB2-1bf, lpa1-1, and lpa1Δ-1 clones. Cells were cultured in
described in (A) and represent the mean±s.e.m. (n=3). ⁎; pb0.05 vs. Control. (C) Effe
serum-free medium for 1 day and exposed to 1 μMLPA for 5 min. Cells were then sub
FLAG tag is present at the N-terminal of LPA1, LPA1Δ and LPA1Δ, FLAG staining
located in the plasma membranes. Arrows indicate internalized LPA1, LPA1Δ and L(Fig. 2A and B). LPA-induced G protein activation was sensitive
to PTX and Rho activation was linked to neurite retraction (data
not shown). Moreover, LPA1Δ and LPA1Δ+ were localized in
plasmamembranes and internalized in response to LPA exposure
(Fig. 2C). All these responses were similar to those observed in
lpa1-1 cells expressing wild type LPA1. Thus, LPA1 mutants
maintained the functionality as an LPA receptor. Interestingly,5S]-GTPγS binding in AB2-1bf, lpa1-1, and lpa1Δ-1 clones. Cells were cultured
5S]-GTPγS binding was 3.3 (AB2-1bf), 18.3 (lpa1-1), and 23.2 (lpa1Δ-1) pmol/
PA) and represent the mean±s.e.m. (n≥3). ⁎; pb0.05 vs. Control. (B) Effects of
serum-free medium for 1 day and subjected to Rho assay. Data are expressed as
cts of LPA on internalization of LPA1, LPA1Δ and LPA1Δ. Cells were cultured in
jected to immunocytochemistry without or with the use of Triton X-100. Because
in Triton X-100-untreated (unpermeabilized) cells reveals that LPA receptors are
PA1Δ. Scale bar, 10 μm.
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cells than those in AB2-1bf and lpa1-1, which will be described
below.
As we maintained these clones in culture, we noticed that
the two lpa1 PDZ mutant clones, lpa1Δ-1 and lpa1Δ+-1,
grew more rapidly than AB2-1bf and lpa1-1, and tended to
form colonies. To determine whether this rapid cell prolifera-
tion was due to serum stimulation or the intrinsic activity of
the mutant LPA receptor, we examined the proliferation of the
cells in serum-free medium. Control AB2-1bf and lpa1-1 cells
showed only a slight increase in cell number under serum-free
conditions (Fig. 3A and B). In contrast, lpa1Δ-1 and lpa1Δ+-
1 showed rapid and remarkable cell proliferation at day 1, and
grew continuously for at least 3 days (Fig. 3A). Expression
levels of LPA receptor proteins in both mutant clones were
slightly higher than that in control lpa1-1 cells (Figs. 1B and
3B). However, similar cell proliferation was also observed in
another lpa1Δ+-expressing clone, lpa1Δ+-3, which showed
lower expression of LPA receptor proteins than that in not
only lpa1Δ-1 and lpa1Δ+-1 cells but also lpa1-1 cells (Fig.
3B). Furthermore, transient expression of lpa1Δ in B103 cells
induced an about 1.5-fold increase in cell population positive
for phospho-histone H3, a mitotic marker (see below),
compared with that for lpa1-expressing cells (data notFig. 3. B103 clones expressing lpa1 lacking the PDZ-binding domain (lpa1Δ, lpa1Δ+
clone (AB2-1bf), lpa1-expressing clone (lpa1-1), lpa1Δ-expressing clone (lpa1Δ-
containing medium for 1 day and washed with serum-free medium at day 0. Cell
expressed as the percentage of cell number on day 0, and are the means± s.e.m. (n = 4
and lpa1Δ+-expressing clones (lpa1Δ+-1 and lpa1Δ+-3). Cell number was determ
parenthesis are relative amounts of expressed receptors corrected using GFP am
micrographs of lpa1-1 and lpa1Δ-1 cells. (D) Incorporation of [3H]-thymidine to DN
cultured in serum-free medium for 1 day and subjected to [3H]-thymidine uptake a
contrastmicrographs ofAB2-1bf, lpa1-1, lpa1Δ-1, and TR cells in the soft agar assay. Sin
were photographed on day 5 and day 10 after plating. Scale bar, 50 μm.shown). These observations indicated that the enhanced cell
proliferation was not due to clonal variation. This enhanced
cell proliferation was often accompanied by colony formation
(Fig. 3C). When lpa1Δ-1 cells were exposed to [3H]-thymidine,
thymidine incorporation into DNAwas 3- to 4-fold higher than
in AB2-1bf or lpa1-1 cells (Fig. 3C). Furthermore, lpa1Δ-1
showed high expression levels of cyclin B1 (Fig. 3C). These
results suggest that mutant clones expressing lpa1Δ and lpa1Δ+
spontaneously progressed through the cell cycle under serum-
free conditions. Interestingly, lpa1Δ-1 cells grew and formed
colonies even in the clonogenic soft agar assay; in contrast,
control AB2-1bf and lpa1-1 cells failed to form colonies in this
assay, even though these cells are essentially neuroblastoma
cells (Fig. 3D). Such proliferation of lpa1Δ-1 cells was
comparable to that of control TR cells (Fig. 3D), murine
immortalized neuroblasts that acquired high transformation
activities by the introduction of the oncogenic large T antigen
and Ras [25].
3.2. LPA1 mutants stimulate the Gi/o and G12/13 pathway to
increase cell proliferation
LPA1 couples to members of three distinct G protein
families, Gi, Gq, and G12/13 to stimulate divergent signal) have enhanced cell cycle progression. (A) Cell proliferation rate of the control
1), and lpa1Δ+-expressing clone (lpa1Δ+-1). Cells were cultured in serum-
number was determined as described in the Materials and Methods. Data are
). (B) Cell proliferation of several lpa1- (lpa1-1 and lpa1-2f), lpa1Δ- (lpa1Δ-1),
ined at day 2, and data are expressed as described in (A). The values in the
ounts, and that in lpa1-1 cells is shown as 1 (n = 2∼4). (C) Phase contrast
A and cyclin B1 expression in AB2-1bf, lpa1-1, and lpa1Δ-1 clones. Cells were
nalysis or western blot analysis. Data are the means±s.e.m. (n=3). (E) Phase
gle cells weremounted in soft agar gel containing serum and cultured. The same cells
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to the stimulation of cell proliferation or the inhibition of cell
death [24,26]. Therefore, we investigated whether the LPA1
mutants spontaneously activated G proteins using two
pharmacological reagents that include pertussis toxin (PTX),
an inhibitor of GPCR-Gi/o coupling, and YM-254890, a
specific Gq inhibitor [27]. Treatment of lpaΔ-1 cells with
PTX resulted in weak but significant suppression of the cell
proliferation, whereas YM-254890 showed no effect on it
(Fig. 4A).
Next, we used three mutant genes that inhibit G protein
signaling to examine the involvement of these G protein
families in the accelerated proliferation of lpa1Δ-1 cells [28].
In these experiments, we detected phosphorylation of histone
H3 as a marker of cell proliferation, because this protein is
phosphorylated at Ser10 during mitosis [29]. The results from
the experiments using PTX and YM-254890 were comparable
with the data from cell proliferation assay (Fig. 4B compared
with Fig. 4A). When lpa1Δ-1 cells were transfected with a
plasmid expressing GRK2ct, which binds Gβγ to inactivate,
marked reduction of the phospho-histone H3–positive cell
population was observed (Fig. 4B). Transfection of lpa1Δ-1
cells with a plasmid expressing RGS4, which inhibits Gαi and
Gαq by activating their GTPases, also significantly reduced
the population (Fig. 4B). Expression of p115RGS, an RGS
domain of p115RhoGEF that inhibits Gα12/13, induced the
extension of the processes in lpa1Δ-1 cells (2∼3-fold increase
in length of processes, compared with that of non-transfected
cells); this was the same phenotype observed in cells treatedFig. 4. Gαi/o and Gα12 family proteins are involved in the enhanced progress of lpa1 m
254890 (YM) on lpa1Δ-1 cell proliferation. Cells were cultured in the absence or pr
(n≥3). ⁎; pb0.05 vs. Control. (B) Effects of PTX, YM-254890, GRK2ct, RGS4 and
of PTX or YM-254890 for 1 day and stained for phospho-histone H3. For transfectio
alkaline phosphatase (BAP), GRKct2, RGS4, or the RGS domain of p115 RhoGEF
transfection. The ratio of phospho-histone H3–positive cells to total transfected cells
Basal [35S]-GTPγS binding activity in AB2-1bf, lpa1-1, and lpa1Δ-1 cells. Cells were
measured. Data are the means±s.e.m. (n≥3).with C3 exoenzyme, indicating that p115RGS inhibited the
G12/13 pathway and downstream Rho. The population of
phospho-histone H3–positive cells in p115RGS-expressing
cells was also lower than that in control cells (Fig. 4B).
Because YM-254890 was ineffective on lpa1Δ-1 cell
proliferation, these results suggested that G proteins, particu-
larly Gi/o and G12/13, were activated and involved in the cell
proliferation of lpa1Δ-1. Indeed, basal [35S]-GTPγS binding
activity, which is thought to correspond to the amounts of
mostly Gi/o, in lpa1Δ-1 was higher than that in control and
lpa1-1 cells (Fig. 4C).
3.3. LPA1 mutants constitutively activate the PI3K-Akt pathway
Next, we examined the signaling pathways acting down-
stream of Gi/o and G12/13, which stimulated the cell
proliferation of lpa1Δ-1. Because MAP kinase species are
major molecules in the Gi-mediated signaling pathway and
are known to play a crucial role in cell proliferation, we
tested MAP kinase inhibitors (PD98059, U0126, SB202190,
SP600125); however, treatment of cells with these com-
pounds for 24 hr appeared to cause cell toxicity at the
concentrations (1∼50 μM) widely used in other studies, and
we did not carry out further studies using these inhibitors.
Nonetheless, western blot analyses for phosphorylated MAP
kinases revealed that there was no significant difference in the
levels of phosphorylated ERK1/2, phosphorylated p38, and
phosphorylated JNK between lpa1-1 and lpa1Δ-1 cells (data
not shown). Thus, MAP kinase pathways were notutant clones through the cell cycle. (A) Effects of pertussis toxin (PTX) and YM-
esence of the inhibitors for 1 day and then counted. Data are the means±s.e.m.
p115RGS on lpa1Δ-1 cell mitosis. Cells were cultured in the absence or presence
n experiment, lpa1Δ-1 cells were transfected with plasmids expressing bacterial
(p115RGS), and stained for protein tags and phospho-histone H3 2 days after
was determined. Data are the means±s.e.m. (n=3). ⁎; pb0.05 vs. Control. (C)
cultured in serum-free medium for 1 day, and [35S]-GTPγS binding activity was
Fig. 5. The PI3K and Akt pathways are activated in lpa1 mutant clones. (A) Effects of wortmannin (Wort), LY294002 (LY29), and deguelin (Deg) on proliferation of
lpa1Δ-1 cells. Cells were cultured in the absence or presence of the inhibitors for 1 day and then counted. Data are the means±s.e.m. (n≥3). ⁎; pb0.05 vs. Control.
(B) Effects of wortmannin, LY294002, and deguelin on death of lpa1Δ-1 cells. Cells were cultured in the absence or presence of the inhibitors for 1 day and counted.
Data are expressed as the percentage of dead cells among total attached cells, and are the means±s.e.m. (n=3). (C) Western blot analysis for the PI3K-Akt pathways in
AB2-1bf, lpa1-1, and lpa1Δ-1 cells. Cells were cultured in the absence or presence of LY294002 (20 μM) for 4 hours and subjected to western blot analysis for
phospho-Akt (Thr308), total Akt, and phospho-GSK3β.
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enhanced cell proliferation.
PI3K is another major molecule in the LPA1-Gi signaling
pathway and its activation is well-known to stimulate its
downstream molecule, Akt, resulting in enhancement of cell
proliferation [30]. When lpa1Δ-1 and lpa1Δ+-1 cells were
treated with the PI3K inhibitors, wortmannin and LY294002,
cell proliferation was significantly blocked in a concentration-
dependent manner without affecting cell viability (Fig. 5A
and B). Deguelin, an Akt inhibitor, also blocked the
proliferation of lpa1Δ-1 and lpa1Δ+-1 cells in a concentra-
tion-dependent manner without inducing cell death (Fig. 5A
and B). Another Akt inhibitor, triciribine, also inhibited the
cell proliferation at 1 μM (data not shown).
Results from our pharmacological experiments suggested
that the PI3K-Akt pathway was constitutively activated in
cells expressing the mutant lpa1. PI3K stimulation leads toactivation as well as phosphorylation of Akt, resulting in the
inhibition of glycogen synthase kinase 3β (GSK3β) by its
phosphorylation [31]. Therefore, we examined the activation
state of these molecules by detecting their phosphorylation
levels in western blot analyses of cell lysates of lpa1Δ-1. Akt
was markedly phosphorylated at Thr 308 and Ser 473 in
lpa1Δ-1 (Fig. 5C and data not shown). Furthermore, levels of
phosphorylation at Ser 9 were elevated in the downstream
molecule GSK3β (Fig. 5C). The phosphorylation of Akt and
GSK3β was reduced by treatment with LY294002 (Fig. 5C).
This reduction induced by LY294002 continued at least up to
24 hr after the addition of the inhibitor (data not shown).
Phosphorylation levels of Akt and GSK3β also seemed to be
higher in lpa1-1 cells than that in control AB2-1bf cells, but
less than that in lpa1Δ-1 cells. This may account for slight
increases in cell proliferation and DNA synthesis observed in
Fig. 3 A, B and D.
Fig. 6. Activated Rho is involved in the enhanced cell cycle progression of lpa1 mutant clones. (A) Effects of C3 exoenzyme on cell proliferation of lpa1Δ-1.
Cells were cultured in the absence or presence of the inhibitor for 1 day, and then counted. Data are expressed as the means±s.e.m. (n=3). ⁎; pb0.05 vs.
Control. (B) Effects of C3 exoenzyme on lpa1Δ-1 cell mitosis. Cells were cultured in the absence or presence of the inhibitor for 1 day, and stained for phospho-
histone H3. Data are expressed as the means±s.e.m. (n=3). ⁎; pb0.05 vs. Control. (C) Rho activity in AB2-1bf, lpa1-1, and lpa1Δ-1 cells. Cells were cultured
in serum-free medium for 1 day, and Rho activity was measured as described in the Materials and Methods. Data are the means±s.e.m. (n=3). (D) RT-PCR
analysis for RhoGEF and G12 family genes in B103 cells. Total RNAs from B103 cells were subjected to RT-PCR using specific primers for p115RhoGEF, PDZ-
RhoGEF, LARG, Gα12 and Gα13 genes.
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Rho
The small GTPase Rho is a major effecter downstream of
LPA1-G12/13, which not only reorganizes the cytoskeleton but
also activates genes related to cell proliferation, such as serum
response element (SRE) [15,24]. We next examined the in-Fig. 7. LPA1-specific antagonists inhibit cell cycle progression of lpa1 mutant clon
lpa1Δ+-1. Cells were cultured in the absence or presence of 1μM Ki16425 or
pb0.05 vs. control. (B) Effects of Ki16425 on [3H]-thymidine incorporation in l
LY294002 for 1 day and subjected to [3H]-thymidine uptake analysis. Data are the
[35S]-GTPγS binding in lpa1Δ-1 cells. Cells were cultured in serum-free medium
presence of Ki16425.volvement of Rho-mediated signaling in the cell proliferation
of lpa1Δ-1 cells. Treatment of lpa1Δ-1 cells with C3
exoenzyme, a Rho inhibitor [32], resulted in significant
suppression of the cell proliferation (Fig. 6A and B). This
suppression was not due to stimulation of cell death (data not
shown). These results suggest that Rho is activated in lpa1
mutant–expressing cells, and indeed, the relative amounts ofes. (A) Effects of Ki16425 and Ki16198 on cell proliferation of lpa1Δ-1 and
Ki16198 for 1 day, and then counted. Data are the means±s.e.m. (n=3). ⁎;
pa1Δ-1 cells. Cells were cultured in the absence or presence of Ki16425 or
means±s.e.m. (n=4). ⁎; pb0.05 vs. Control. (C) Effects of Ki16425 on basal
for 1 day and subjected to [35S]-GTPγS binding assay in the absence or
Fig. 8. Expression of LPA1 mutant receptors also stimulates cell proliferation
of non-tumor 3T3 fibroblasts. (A) Cell proliferation of the control 3T3 cell
clone (3T3-AB), lpa1-expressing clone (3T3-a1), lpa1Δ-expressing clone
(3T3-a1Δ), and lpa1Δ+-expressing clone (3T3-a1Δ+). The cells were
subjected to a cell proliferation assay in the presence of 0.5% FCS,
essentially as described in the legend of Fig. 3. Data are expressed as the
percentage of cell number (absorbance) on day 0, and are the means±s.e.m.
(n=4). (B) Phase contrast micrographs of 3T3-AB, 3T3-a1, and 3T3-a1Δ
cells in a clonogenic soft agar assay. Single cells were mounted in soft agar
gel containing serum and cultured. The same cells were photographed on day
10 and day 20 after plating. Scale bar, 50 μm.
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not lpa1-1 cells (Fig. 6C).
It has been reported that the PDZ-binding domain of LPA1
can physically bind PDZ-RhoGEF and LARG, and LPA1
lacking the domain lost the ability to bind these functional
molecules, resulting in a failure to stimulate the Rho pathway
[20]. RT-PCR analysis showed that B103 cells expressed the
genes of RhoGEF and LARG as well as p115RhoGEF,
another RhoGEF that does not contain the PDZ domain but
interacts with G13 to stimulate Rho [33,34] (Fig. 6D). In
addition, B103 cells were also shown to express both Gα12
and Gα13 genes (Fig. 6D). Thus, LPA1 lacking the domain
may retain the ability to stimulate the Rho pathway through
the interaction between G12/13 and p115RhoGEF.
3.5. Specific LPA1 antagonists inhibit the proliferation of
lpa1Δ-1 and lpa1Δ+-1 cells
Two specific LPA1 antagonists, Ki16425 and Ki16198,
have recently been developed and shown to inhibit LPA1-
mediated responses, such as neurite retraction [35] (data not
shown). To examine whether these compounds are not only
antagonists but also inverse agonists, we tested whether they
would suppress the cell proliferation induced by constitu-
tively active LPA1 mutant receptor. The proliferation of
lpa1Δ-1 and lpa1Δ+-1 cells cultured in the presence of 1 μM
Ki16425 or Ki16198 was inhibited by about 70% (Fig. 7A).
Moreover, lpa1Δ-1 cells treated with Ki16425 showed a
concentration-dependent reduction in intrinsic [3H]-thymidine
incorporation and [35S]-GTPγS binding activity in cell
membranes (Fig. 7B and C). The culture supernatant of
lpa1Δ-1 cells could not induce neurite retraction in lpa1-1
cells (data not shown), indicating that lpa1Δ-1 cells did not
produce an LPA-like activity stimulating LPA1Δ in an
autocrine manner. Therefore, both antagonists also acted as
inverse agonists.
3.6. LPA1 mutant–expressing 3T3 fibroblasts form colonies in
soft agar
Finally, we examined whether the LPA1 mutant could
stimulate cell proliferation in other types of cells, particularly
non-tumor cells. For this purpose, we selected mouse 3T3
fibroblasts. We established 3T3 fibroblast clones expressing
lpa1, lpa1Δ, or lpa1Δ+ and assessed the proliferation of these
cells in a cell proliferation assay in the presence of 0.5% FCS.
Under these conditions, control (3T3-AB) and lpa1 (3T3-a1)
clones did not survive well (Fig. 8A), but clones expressing
lpa1Δ (3T3-a1Δ) and lpa1Δ+ (3T3-a1Δ+) not only survived
but also grew remarkably well, as the B103 mutant clones
had.
Next, 3T3-AB, 3T3-a1, and 3T3-a1Δ cells were subjected
to the clonogenic soft agar assay. Colony formation was
observed only in the lpa1 mutant clone, although these
colonies were formed slowly and were smaller in size than
those of the lpa1Δ-1 and lpa1Δ+-1 B103 mutants (Fig. 8B,
compare with Fig. 3E). These results indicate that lpa1mutants are capable of inducing the oncogenic transformation
of 3T3 fibroblasts.
4. Discussion
In the present study, we demonstrated that an LPA1 mutant
lacking the PDZ-binding domain is constitutively active and
might be oncogenic. This finding provides us with two in-
teresting aspects to pursue: First, abnormalities in LPA sig-
naling might be involved in tumorigenesis and tumor growth,
and second, this constitutively active mutant LPA1 can be
used to investigate LPA1-mediated cellular signaling and
biological relevance.
4.1. LPA1 lacking SerValVal is constitutively active and
stimulates cell proliferation through the PI3K-Akt and Rho
pathways
LPA1 couples to proteins of the Gi, Gq, and G12 families
[15,16]. Activation of Gi inhibits adenylyl cyclase and
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stimulation results in the elevation of the intracellular Ca2+
concentration and activation of PKC [15]. The G12 family is
linked to activation of the Rho pathway, leading to
stimulation of SRE, which functions in cell proliferation,
and cytoskeletal rearrangement [24]. Our results from
experiments using PTX, YM-254890, GRK2ct, RGS4, and
p115RGS suggest that constitutive activation of the Gi and
G12 families is primarily involved in the cell proliferation of
the mutant cells. Gβγ liberated from Gi may stimulate PI3K-
Akt pathways, and stimulation of G12 family proteins may
lead to RhoGEF activation, followed by Rho stimulation.
However, the degree of PTX-induced inhibition of cell
proliferation was smaller than that by the inhibitors for
PI3K and Akt. This finding raises the possibility that
constitutive activation of the PI3K-Akt axis may also be, in
part, induced through G12/13 or other G proteins. Indeed,
oncogenic mutant G12 has been demonstrated to activate the
PI3K-Akt signaling pathway, although this is mediated
through induction of platelet-derived growth factor receptor
expression [36]. In contrast to lpa1Δ-1 cells, activation of Akt
but not Rho was observed in lpa1-1 cells, which show no or
slight increase in cell proliferation. Thus, dual or co-operative
activation of PI3K-Akt and Rho pathways may be required to
induce complete cell proliferation.
Our data indicate that LPA1 lacking the domain still
stimulates the Rho pathway, possibly through the interactions
between G12/13 and p115RhoGEF. This is contrast to the
previous report that LPA1 overexpressed in HEK293 cells
physically can bind PDZ-RhoGEF and LARG through its
PDZ-binding domain, and LPA1 lacking the domain lost the
ability to bind these functional molecules, resulting in a
failure to stimulate the Rho pathway [20]. However, HEK293
cells were also found to express p115RhoGEF gene as well as
G12 and G13 genes (our unpublished data). Although we
cannot explain this discrepancy yet, transiently-overexpressed
LPA1 might preferentially activate the interactions of G12/13
with PDZ-RhoGEF and LARG, rather than p115RhoGEF.
Further analysis on endogenous LPA1–mediated signaling
would be needed.
4.2. The PDZ-binding domain of LPA1 influences the functions
of the receptor
Given that LPA1Δ is a constitutively active form, the PDZ-
binding domain may play an inhibitory role in LPA1-mediated
signal transduction. One possible, simple interpretation is that
this domain physically inhibits the interaction between LPA1
and G proteins. If this is the case, binding of LPA to wild
type LPA1 should result in activation of G proteins by
releasing the inhibition, and LPA1 lacking the PDZ-binding
domain should no longer respond to LPA. However, LPA1Δ
was not only intrinsically activated but also able to respond to
LPA (Fig. 2). This observation, therefore, cannot be explained
by the simple interpretation above mentioned. Rather, this
domain may have a regulatory role in receptor function by
interacting with other proteins, such as GIPs. Although PDZ-RhoGEF has been shown to be a GIP for LPA1 [20], other
GIPs may exist. Indeed, many GIPs have been identified as
functional molecules controlling the targeting, trafficking, and
signaling of GPCRs, and two or more GIPs can associate with
single GPCR [17,37]. For instance, 5-HT2 receptors have also
been reported to associate with several types of GIPs through
their PDZ-binding domains, although their functions remain
unclear [17]. The β1- and β2-adrenergic receptors also
requires interactions between its PDZ-binding domain and
several PDZ-containing proteins for physiologic signaling
[37–40]. Identification of GIPs that interact with the
SerValVal of LPA1 in addition to PDZ-RhoGEF would be
interesting.
4.3. Is the LPA1 mutant an oncogenic receptor?
The clonogenic soft agar assay has been widely used to
determine the oncogenic activity of genes. The robust pro-
liferation and expansion of neuroblastoma and fibroblast cells
expressing lpa1Δ in soft agar demonstrated that LPA1 lacking
the PDZ-binding domain might constitutively activate onco-
genic signaling pathways and suggested that such a mutation
could result in tumorigenesis and tumor growth. We
sequenced approximately 300 nucleotides of a cDNA
encoding the C-terminus of LPA1 prepared from 8 different
types of human cancer cells that expressed high levels of lpa1
mRNA [41]. However, no mutation was detected within this
region in any of the cells examined (unpublished observa-
tion). Whether the mutation that produces the C-terminus
deletion occurs and causes tumorigenesis in human tissues is
therefore still unclear.
Recently, we also found that the promoter region of lpa1 is
highly methylated in rodent tumor cells, including B103 and rat
hepatoma RH7777 cells, neither of which express the lpa1 gene
endogenously, and that demethylation restores the expression of
lpa1 in these cells [42]. Conversely, the lpa1 promoter is not
methylated in normal rat brain and liver, which express levels of
lpa1 detectable by RT-PCR [42]. These findings suggest that
lpa1 functions as an anti-oncogenic gene. Thus, both the
mutation and methylation of the lpa1 gene might be involved in
tumorigenesis or tumor growth. Comprehensive clinical
research using tumor tissues would be necessary to clarify
this idea.
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